<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>OncoSphere Analytics | Lung Cancer Therapeutics</title>
    <style>
        /* ... (Le style CSS reste le m√™me que l'original) ... */
        body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; background: linear-gradient(135deg, #00c6ff 0%, #0072ff 100%); color: #333; }
        .molecule-card { border-left: 5px solid #007bff; }
        .molecule-card.featured { border-left-color: #ffc107; }
        .badge { background: #ffc107; }
        th { background: linear-gradient(135deg, #00c6ff 0%, #0072ff 100%); }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <div class="header-content">
                <div class="logo-section">
                    <div>
                        <h1>OncoSphere Analytics</h1>
                        <p class="subtitle">Pioneering Targeted Therapies for Lung Cancer</p>
                    </div>
                </div>
            </div>
        </header>

        <section class="hero" id="mission">
            <h2>üéØ Mission Statement</h2>
            <p>
                Lung cancer is the leading cause of cancer-related death worldwide. Our platform focuses on the pharmacology of next-generation targeted therapies and immunotherapies for Non-Small Cell Lung Cancer (NSCLC), providing crucial data for researchers and clinicians.
            </p>
        </section>

        <h2 id="molecules" style="color: white; margin: 30px 0 20px; text-align: center; font-size: 2em;">
            üèÜ Top 5 Therapeutic Agents
        </h2>
        
        <div class="molecules">
            <div class="molecule-card featured">
                <h3>
                    Osimertinib (Tagrisso)
                    <span class="badge">RANK #1</span>
                </h3>
                <div class="molecule-info">
                    <p><strong>ChEMBL ID:</strong> CHEMBL3301610</p>
                    <p><strong>Target:</strong> EGFR (T790M-mutated) Inhibitor</p>
                    <p><strong>Key Advantage:</strong> High CNS penetration (for brain mets)</p>
                    <p><strong>Bioavailability:</strong> ~70%</p>
                    <p><strong>Half-life:</strong> ~48 hours</p>
                </div>
                <div class="efficacy-bar"><div class="efficacy-fill" style="width: 95%;">Efficacy: 95%</div></div>
            </div>

            <div class="molecule-card">
                <h3>Alectinib (Alecensa)</h3>
                <div class="molecule-info">
                    <p><strong>ChEMBL ID:</strong> CHEMBL2424782</p>
                    <p><strong>Target:</strong> ALK Inhibitor (2nd Gen)</p>
                    <p><strong>Bioavailability:</strong> ~37% (with food)</p>
                    <p><strong>Half-life:</strong> 33 hours</p>
                    <p><strong>Key Advantage:</strong> Superior CNS efficacy</p>
                </div>
                <div class="efficacy-bar"><div class="efficacy-fill" style="width: 91%;">Efficacy: 91%</div></div>
            </div>

            <div class="molecule-card">
                <h3>Pemetrexed (Alimta)</h3>
                <div class="molecule-info">
                    <p><strong>Type:</strong> Chemotherapy</p>
                    <p><strong>Target:</strong> Thymidylate synthase</p>
                    <p><strong>Route:</strong> IV infusion</p>
                    <p><strong>Key Indication:</strong> Non-squamous NSCLC</p>
                    <p><strong>Requirement:</strong> Vitamin B12/Folic Acid Supplement</p>
                </div>
                <div class="efficacy-bar"><div class="efficacy-fill" style="width: 78%;">Efficacy: 78%</div></div>
            </div>

            <div class="molecule-card">
                <h3>Gefitinib (Iressa)</h3>
                <div class="molecule-info">
                    <p><strong>ChEMBL ID:</strong> CHEMBL941</p>
                    <p><strong>Target:</strong> EGFR Inhibitor (1st Gen)</p>
                    <p><strong>Bioavailability:</strong> ~60%</p>
                    <p><strong>Half-life:</strong> 41 hours</p>
                    <p><strong>Toxicity Concern:</strong> Hepatotoxicity</p>
                </div>
                <div class="efficacy-bar"><div class="efficacy-fill" style="width: 75%;">Efficacy: 75%</div></div>
            </div>
            
            <div class="molecule-card">
                <h3>Erlotinib (Tarceva)</h3>
                <div class="molecule-info">
                    <p><strong>ChEMBL ID:</strong> CHEMBL939</p>
                    <p><strong>Target:</strong> EGFR Inhibitor (1st Gen)</p>
                    <p><strong>Bioavailability:</strong> ~60%</p>
                    <p><strong>Half-life:</strong> 36 hours</p>
                    <p><strong>Note:</strong> Smoking reduces efficacy</p>
                </div>
                <div class="efficacy-bar"><div class="efficacy-fill" style="width: 72%;">Efficacy: 72%</div></div>
            </div>
        </div>
        
        <section class="comparison-table" id="comparison">
            <h2 style="color: #2c3e50; margin-bottom: 20px;">üìà Head-to-Head Comparison (1st Line)</h2>
            <table>
                <thead>
                    <tr>
                        <th>Drug</th>
                        <th>Target</th>
                        <th>Median PFS</th>
                        <th>CNS Efficacy</th>
                        <th>Safety Profile</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Osimertinib</strong></td>
                        <td>EGFR</td>
                        <td>18.9 months</td>
                        <td>‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê</td>
                        <td>‚≠ê‚≠ê‚≠ê‚≠ê</td>
                    </tr>
                    <tr>
                        <td><strong>Alectinib</strong></td>
                        <td>ALK</td>
                        <td>34.8 months</td>
                        <td>‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê</td>
                        <td>‚≠ê‚≠ê‚≠ê‚≠ê</td>
                    </tr>
                    <tr>
                        <td><strong>Gefitinib</strong></td>
                        <td>EGFR</td>
                        <td>9.7 months</td>
                        <td>‚≠ê‚≠ê</td>
                        <td>‚≠ê‚≠ê‚≠ê</td>
                    </tr>
                    <tr>
                        <td><strong>Erlotinib</strong></td>
                        <td>EGFR</td>
                        <td>11.0 months</td>
                        <td>‚≠ê‚≠ê</td>
                        <td>‚≠ê‚≠ê</td>
                    </tr>
                    <tr>
                        <td><strong>Pemetrexed + Chemo</strong></td>
                        <td>DNA Synthesis</td>
                        <td>8.4 months</td>
                        <td>‚≠ê</td>
                        <td>‚≠ê‚≠ê</td>
                    </tr>
                </tbody>
            </table>
        </section>

        <footer>
            <p>¬© 2025 OncoSphere Analytics | For Educational and Research Purposes Only</p>
        </footer>
    </div>
</body>
</html>